Literature DB >> 16816887

Relationship between histological subtypes and clinical characteristics at presentation and outcome in biopsy-proven temporal arteritis. Identification of a relatively benign subgroup.

E J ter Borg1, H C M Haanen, C A Seldenrijk.   

Abstract

Temporal arteritis (TA) may offer major complications, whilst high dosage of prednisone may result in serious side effects. We tried to identify a subgroup of TA, which can be treated with a lower dosage of prednisone. Retrospectively, clinical and laboratory data were studied at presentation, as well as the outcome in 44 consecutive patients with biopsy-proven temporal arteritis. These data were related to three particular histological subgroups, (a) classical giant cell arteritis, (b) atypical arteritis, and (c) 'healed arteritis', defined according to Allsop and Gallagher (The American Journal of Surgical Pathology 5:317-332, 1981). At presentation in subgroup c, erythrocyte sedimentation rate was lower and the level of haemoglobin was higher than in the other two subgroups. During follow-up in the healed arteritis group, reactivation, recurrence, or early death were not observed, whilst prednisone dosage after 2 and 3 years was lower compared to subgroup b. Major complications (permanent blindness and cerebrovascular accident) were only observed in subgroups a and b. We believe that the healed arteritis subgroup represents a relatively benign subgroup with a mild clinical presentation and a good prognosis. Therefore, a much lower initial prednisone dosage (15 mg/day) is suggested for patients in subgroup c than in the other two subgroups (40-60 mg/day).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16816887     DOI: 10.1007/s10067-006-0332-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  5 in total

Review 1.  Polymyalgia rheumatica and giant cell arteritis.

Authors:  J M Evans; G G Hunder
Journal:  Rheum Dis Clin North Am       Date:  2000-08       Impact factor: 2.670

2.  The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis.

Authors:  G G Hunder; D A Bloch; B A Michel; M B Stevens; W P Arend; L H Calabrese; S M Edworthy; A S Fauci; R Y Leavitt; J T Lie
Journal:  Arthritis Rheum       Date:  1990-08

3.  Polymyalgia rheumatica and giant cell arteritis.

Authors:  L A Healey; F Parker; K R Wilske
Journal:  Arthritis Rheum       Date:  1971 Jan-Feb

4.  Temporal artery biopsy in giant-cell arteritis. A reappraisal.

Authors:  C J Allsop; P J Gallagher
Journal:  Am J Surg Pathol       Date:  1981-06       Impact factor: 6.394

5.  Presenting features and outcomes in patients undergoing temporal artery biopsy. A review of 98 patients.

Authors:  W L Chmelewski; K M McKnight; C A Agudelo; C M Wise
Journal:  Arch Intern Med       Date:  1992-08
  5 in total
  4 in total

1.  Clinical course and management of a consecutive series of patients with "healed temporal arteritis".

Authors:  Yvonne C Lee; Robert F Padera; Erika H Noss; Anne H Fossel; Don Bienfang; Matthew H Liang; William P Docken
Journal:  J Rheumatol       Date:  2011-12-01       Impact factor: 4.666

Review 2.  Review of Giant cell arteritis.

Authors:  Joseph G Chacko; J Anthony Chacko; Michael W Salter
Journal:  Saudi J Ophthalmol       Date:  2014-11-01

3.  Description and Validation of Histological Patterns and Proposal of a Dynamic Model of Inflammatory Infiltration in Giant-cell Arteritis.

Authors:  José Hernández-Rodríguez; Giuseppe Murgia; Irama Villar; Elías Campo; Sarah L Mackie; Aruna Chakrabarty; Elizabeth M A Hensor; Ann W Morgan; Carme Font; Sergio Prieto-González; Georgina Espígol-Frigolé; Josep M Grau; Maria C Cid
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

4.  Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis.

Authors:  Sara Monti; Ana F Águeda; Raashid Ahmed Luqmani; Frank Buttgereit; Maria Cid; Christian Dejaco; Alfred Mahr; Cristina Ponte; Carlo Salvarani; Wolfgang Schmidt; Bernhard Hellmich
Journal:  RMD Open       Date:  2019-09-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.